67. Polycystic kidney disease Clinical trials / Disease details

Clinical trials : 216 / Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02127437 (ClinicalTrials.gov)	September 19, 2014	2/4/2014	Lanreotide In Polycystic Kidney Disease Study	Lanreotide In Polycystic Kidney Disease Study	Autosomal Dominant Polycystic Kidney Disease (ADPKD	Drug: Lanreotide;Drug: saline	Assistance Publique - Hôpitaux de Paris	IPSEN pharmaceutical company, Boulogne-Billancourt, France	Completed	18 Years	N/A	All	159	Phase 3	France
2	NCT01616927 (ClinicalTrials.gov)	June 2012	6/6/2012	Study of Lanreotide to Treat Polycystic Kidney Disease	The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Lanreotide	University Medical Center Groningen	Leiden University Medical Center;Erasmus Medical Center;Radboud University	Active, not recruiting	18 Years	60 Years	All	300	Phase 3	Netherlands
3	EUCTR2011-005017-37-NL (EUCTR)	30/05/2012	21/05/2012	To investigate the effect of Lanreotide on renal function decline in ADPKD patients	A randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study	First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume. MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Somatuline Autogel Product Name: Lanreotide Product Code: BIM 23014 INN or Proposed INN: Lanreotide Other descriptive name: LANREOTIDE ACETATE	DIPAK Consortium	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
4	NCT01354405 (ClinicalTrials.gov)	May 2011	13/5/2011	Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)	The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease	Polycystic Liver Disease	Drug: Lanreotide	Radboud University	Ipsen	Completed	18 Years	70 Years	Both	43	N/A	Netherlands
5	NCT00771888 (ClinicalTrials.gov)	April 2008	13/10/2008	Open-Label Extension of LOCKCYST Trial	Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers	Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney;Autosomal Dominant	Drug: lanreotide	Radboud University	Ipsen	Active, not recruiting	18 Years	88 Years	Both	54	Phase 2/Phase 3	Belgium;Netherlands
6	NCT00565097 (ClinicalTrials.gov)	October 2007	28/11/2007	Lanreotide as Treatment of Polycystic Livers	Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers	Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney, Autosomal Dominant	Drug: Placebo;Drug: Lanreotide	Radboud University	Ipsen	Completed	18 Years	88 Years	Both	38	Phase 2/Phase 3	Belgium;Netherlands